NASDAQ$NPCE
Neuropace Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
NeuroPace reported a 41% increase in revenue to $18.0 million for Q4 2023, driven by increased RNS System sales and DIXI Medical product revenue, while reducing cash burn to $3.4 million.
NeuroPace announced record full year 2023 revenue of $65.4 million. Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022. The company provides full-year 2024 revenue guidance of between $73-$77 million.
- Total revenue in Q4 2023 grew 41% to $18.0 million compared to Q4 2022.
- Full year 2023 revenue increased 44% to $65.4 million compared to 2022.
- Gross margin for Q4 2023 was 75.2% compared to 68.8% in Q4 2022.
- Cash burn in Q4 2023 was $3.4 million, compared to $7.9 million in Q4 2022.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$18M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
NeuroPace expects revenue growth to be primarily driven by increasing sales of its RNS System and higher sales of DIXI Medical stereo EEG products, while replacement implant revenue is expected to decline in 2024 versus 2023.
Tailwinds
- Total revenue to range between $73 million and $77 million, representing growth of 12% to 18% over 2023
- Gross margin to range between 72% and 74%
- Increasing sales of its RNS System
- Higher sales of DIXI Medical stereo EEG products
- Focus on operating discipline
Headwinds
- Replacement implant revenue is expected to decline in 2024 versus 2023
- Total operating expenses to range between $80 million and $84 million, including approximately $12 million in stock-based compensation, a noncash expense
- Inherent uncertainties, risks, and assumptions that are difficult to predict
- Actual outcomes and results could differ materially due to a number of factors
- Market expansion depends on clinical trial results and indication expansion
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.1%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | — | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro